Terns Pharmaceuticals (TERN) Enterprise Value (2020 - 2023)
Terns Pharmaceuticals (TERN) has disclosed Enterprise Value for 4 consecutive years, with -$266.6 million as the latest value for Q3 2023.
- For the quarter ending Q3 2023, Enterprise Value fell 42.35% year-over-year to -$266.6 million, compared with a TTM value of -$266.6 million through Sep 2023, down 42.35%, and an annual FY2022 reading of -$162.9 million, up 1.85% over the prior year.
- Enterprise Value was -$266.6 million for Q3 2023 at Terns Pharmaceuticals, up from -$285.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$11.7 million in Q1 2020 and bottomed at -$285.6 million in Q2 2023.
- Average Enterprise Value over 4 years is -$154.7 million, with a median of -$166.0 million recorded in 2021.
- The sharpest move saw Enterprise Value plummeted 1572.2% in 2021, then increased 24.46% in 2022.
- Year by year, Enterprise Value stood at -$74.9 million in 2020, then tumbled by 121.74% to -$166.0 million in 2021, then grew by 1.85% to -$162.9 million in 2022, then plummeted by 63.65% to -$266.6 million in 2023.
- Business Quant data shows Enterprise Value for TERN at -$266.6 million in Q3 2023, -$285.6 million in Q2 2023, and -$282.6 million in Q1 2023.